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Abstract
Background: Monetary incentives in research are frequently used to support participant recruitment and retention. However,
there are scant empirical data regarding how researchers decide upon the type and amount of incentives offered. Likewise, there
is little guidance to assist study investigators and institutional review boards (IRBs) in their decision-making on incentives.
Monetary incentives, in addition to other factors such as the risk of harm or other intangible benefits, guide individuals’ decisions
to enroll in research studies. These factors emphasize the need for evidence-informed guidance for study investigators and IRBs
when determining the type and amount of incentives to provide to research participants.
Objective: The specific aims of our research project are to (1) characterize key stakeholders’ views on and assessments of
incentives in biomedical HIV research; (2) reach consensus among stakeholders on the factors that are considered when choosing
research incentives, including consensus on the relative importance of such factors; and (3) pilot-test the use of the guidance
developed via aims 1 and 2 by presenting stakeholders with vignettes of hypothetical research studies for which they will choose
corresponding incentive types.
Methods: Our 2-year study will involve monthly, active engagement with a stakeholder advisory board of people living with
HIV, researchers, and IRB members. For aim 1, we will conduct a nationwide survey (N=300) among people living with HIV to
understand their views regarding the incentives used in HIV research. For aim 2, we will collect qualitative data by conducting
focus groups with people living with HIV (n=60) and key informant interviews with stakeholders involved in HIV research
(people living with HIV, IRB members, and biomedical HIV researchers: n=36) to extend and deepen our understanding of how
incentives in HIV research are perceived. These participants will also complete a conjoint analysis experiment to gain an
understanding of the relative importance of key HIV research study attributes and the impact that these attributes have on study
participation. The data from the nationwide survey (aim 1) will be triangulated with the qualitative and conjoint analysis data
(aim 2) to create 25 vignettes that describe hypothetical HIV research studies. Finally, individuals from each stakeholder group
will select the most appropriate incentive that they feel should be used in each of the 25 vignettes (aim 3).
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Results: The stakeholder advisory board began monthly meetings in March 2021. All study aims are expected to be completed
by December 2022.
Conclusions: By studying the role of incentives in HIV clinical trial participation, we will establish a decision-making paradigm
to guide the choice of incentives for HIV research and, eventually, other types of similar research and facilitate the ethical
recruitment of clinical research participants.
Trial Registration: ClinicalTrials.gov NCT04809636; https://clinicaltrials.gov/ct2/show/NCT04809636
International Registered Report Identifier (IRRID): DERR1-10.2196/33608
(JMIR Res Protoc 2021;10(11):e33608) doi: 10.2196/33608
KEYWORDS
incentives; ethics; research participation; stakeholder advisory board; HIV

Introduction

(eg, local norms and the cost of living), and variabilities in
institutional practices [9].

Background

The documentation of incentive types and amounts in
consideration of these factors is lacking [20,21]. The most recent
comprehensive study of payment in US-based research
(conducted in 2005) described 467 publications of clinical
studies, of which fewer than 25% reported payment amounts
[9]. Furthermore, a review by Dickert and colleagues [22]
showed that less than one-fifth of US institutions knew which
of their studies provided payment.

Providing incentives, which are defined as “payment[s]
(including money, gifts, and services) to research volunteers
for participation in studies” [1], is a widely accepted and
common practice in HIV clinical research [2-6]. Although some
research suggests that altruism is a primary motivation for
research participation [3,5,6], incentives are typically necessary
for ensuring sufficient participant enrollment in research [7-9],
including high-risk trials and other studies that may result in
negative health outcomes for participants [10,11]. Although it
is known that the incentives provided among similar studies
can vary greatly [9,12], little research exists on the factors that
are considered important for determining appropriate incentives.
This raises concerns about the possibility of unduly influencing
participation in research due to the type and quality of the
incentives provided [8,13-16].
Many factors influence the type and quality of incentives,
including risks, benefits, burdens, historical precedents, study
procedures, time commitments, study budgets, institutional
review board (IRB) recommendations, advice from other
investigators, and local regulations [9,12-14]. In the field of
HIV treatment and cure-related research, additional factors
regarding incentives are considered, since participants can face
greater than minimal risk (eg, the risk of interrupting HIV
treatment). In HIV cure research, the outlook for direct
individual benefit is low, and participants may face additional
social vulnerabilities (eg, belonging to a sexual minority group
and having a lower socioeconomic status), which can affect
motivations to participate in such research [6,13,16,17]. These
factors emphasize the need for ethical incentive decision-making
guidelines, especially in biomedical HIV research.
Ideally, incentives encourage participation and participant
retention in clinical and behavioral research without causing
undue inducement [9,15,18,19]. However, balance for incentive
types and amounts can be difficult to establish when significant
variability exists across studies. It is important to consider the
spectrum of researchers’ attitudes regarding the ethics of
incentives as well as beliefs about what IRBs permit. This is
reflected by the varying monetary amounts that are approved
by IRBs and issued across similar protocols, especially those
that are issued at the same institution [9]. Other factors could
include study procedures, participants’ setting characteristics
https://www.researchprotocols.org/2021/11/e33608
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An important topic that will be addressed in our study is the
characterization of undue inducement. Even when institutions
track payments, significant differences often exist in IRBs’
understanding of undue influence, which is sparsely studied
[9,15,21,23]. The Council for International Organizations of
Medical Sciences Guidelines state that “[c]ompensation is not
meant to compensate for the risk that participants agree to
undertake” [24]. However, it is possible that stakeholders
(research participants, IRB members, and study investigators)
may nonetheless believe that an incentive should compensate
for risk and that providing payments is a way of making risks
acceptable to participants [3]. We will explore ethical issues
related to this topic and consider incentives that may be viewed
as too small.
Little is known about the actual effect that incentives have on
clinical research participation. In large part, this is due to a lack
of comprehensive tracking, a lack of mandates for investigators
to record participant payments, and the inconsistent reporting
of incentives in published research manuscripts [25-29]. Even
in multisite or multinational research, wide variability in
incentivizing has been observed. For example, to control overand underincentivizing, South Africa developed standardized
payments for participants [30], while Brazil prohibited the
provision of monetary payments for clinical trials [31]. Outside
of these rare cases, the absence of a reference for comparison
burdens researchers with the need to determine appropriate
incentives on a case-by-case basis.
Decisions on acceptable payment should not be made without
a clear understanding of currently offered incentives, or else we
will continue to develop personal biases that are not critically
assessed. Our study aims to lay the groundwork that will guide
this emerging area of inquiry toward the establishment of a
more systematic study that will develop a framework for
JMIR Res Protoc 2021 | vol. 10 | iss. 11 | e33608 | p. 2
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determining incentives. Ultimately, we will provide a resource
so that decisions on incentive types and amounts are guided by
transparent, concrete, and evidence-based decision-making. In
the absence of an incentive decision-making tool, it will continue
to be impossible to determine the equity of incentives that are
offered across similar studies [27].
We are interested to know if stakeholders perceive incentives
as a benefit of research participation. Federal law expressly
prohibits the consideration of providing compensation to offset
risks [1,32]. This is because of concerns that a very risky study
may be perceived as having an acceptable risk-benefit ratio
simply because it pays a lot of money. It is possible however
that participants still consider money to be a benefit of research
participation, at least beyond reimbursement. We seek to
determine if incentives make the perceived risk-benefit ratio
more favorable or acceptable and if they affect the perceived
balance of risks and potential benefits [3,33]. There may be
ethical issues when incentives sway the decision-making
capacities of individuals by making them ignore the risks
involved rather than balance the risks and benefits [17,19,33].
We will also ask stakeholders for specific recommendations to
improve the description of payments in the informed consent
process.

Specific Aims
The specific aims of our project are to (1) characterize key
stakeholders’ views on and assessments of incentives, (2) reach
consensus among stakeholders on the factors that are considered
important when choosing incentives and on the relative
importance of these factors, and (3) pilot-test the use of the
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guidance developed via aims 1 and 2 by using vignettes of
hypothetical research studies. These vignettes will present a
variety of HIV research studies that differ in risks, procedures,
and incentives.
The projected outcomes from these aims include the
determination of different stakeholder groups’ views about
incentives, shared decision-making on relevant study factors to
consider when deciding on an ethical incentive, and an
understanding of how well our chosen factors predict incentive
decision-making. We hypothesize that potential study
participants make trade-offs based on the characteristics of a
research study when deciding on whether to participate. For
example, after a study’s risks are weighed against the benefits
and incentives offered, a decision to participate will be made.

Methods
Overview
We will use an explanatory, sequential, mixed methods study
design to address each study aim. Specific study activities will
include the establishment of a stakeholder advisory board
(SAB); a national survey of people living with HIV; focus
groups and interviews with key stakeholders; a consumer
marketing experiment (conjoint analysis [CJA]) to understand
the relative importance of different incentive types and amounts
in research participation decision-making; and finally, a pilot
test of ethical decision-making, which will be conducted by
providing case vignettes to stakeholders to determine appropriate
incentives (Figure 1). The study will last 24 months (Table S1
in Multimedia Appendix 1).
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Figure 1. Study aims and process. IRB: institutional review board.

Develop an SAB
We will convene a national, 12-member SAB comprised of
people living with HIV, IRB members, and HIV researchers to
review and provide ongoing feedback and suggestions for the
implementation of each study component. The SAB will meet
each month via Zoom (Zoom Video Communications Inc) for
90 minutes throughout the study period and receive US $30 for
each meeting attended. SAB members will provide their
stakeholder perspective to review and amend proposed study
materials, help make decisions on study procedures, pilot study
activities, and assist with participant recruitment.

https://www.researchprotocols.org/2021/11/e33608
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Aim 1: Conduct a National Survey of People Living
With HIV
We will conduct a single, internet-based survey with
English-speaking US residents who identify as people living
with HIV. The 20-minute survey will assess demographic
characteristics and how incentives affect the willingness to
participate in HIV research. We will include screening questions
to ensure that each survey respondent meets our inclusion
criteria (Table S2 in Multimedia Appendix 1). Participants who
pass the screening questions and complete the survey will be
compensated with US $7.
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Participants will be recruited through Amazon Mechanical Turk,
and the survey will be programmed into Qualtrics (Qualtrics
International Inc). Amazon Mechanical Turk is a commonly
used platform for recruiting targeted populations and collecting
high-quality data, and it is comparable to US web-based survey
panels [34-36]. We expect that the purposive national sample
will represent people living with HIV who are diverse with
respect to their ages, genders, sexual orientations, races and
ethnicities, times since diagnosis, and histories of participation
in clinical studies. We will analyze survey data by using
Stata/SE 17 (StataCorp LLC). We will calculate descriptive
statistics for all study variables and use linear, logistic, and
multinomial regression models to identify any significant
associations between demographic characteristics and key
dependent variables.

Aim 2: Facilitate Focus Groups and Interviews With
Key Stakeholders
We will conduct 6 focus groups with people living with HIV
(6-10 people per group; up to 60 people in total) to obtain
perceptions on the ethics of incentives in research. We especially
hope to capture the views of historically underrepresented
populations, including older men and women aging with HIV,
cisgender and transgender women living with HIV, and adults
(aged ≥18 years) of color. We will also focus on recruiting
people living with HIV who have comorbid diagnoses of
depression, heart disease, and arthritis to ensure that our results
are applicable beyond HIV research.
Focus groups will last approximately 1 hour and 40 minutes,
will be conducted via videoconferencing, and will be recorded.
Participants without sufficient technology for video streaming
will be permitted to join discussions via phone. Each participant
will receive a US $25 gift card. A key advantage of focus groups
is that they help evoke conversations, but they may also foster
groupthink [37]. We will mitigate this drawback by having a
strong leader who is trained in effective focus group facilitation.
By doing so, we will also ensure the receipt of input from all
participants, help minimize the amount of irrelevant discussions,
and prevent people from speaking over each other. Furthermore,
having a strong focus group leader will help transcriptions run
smoothly and increase the decipherability of audio data. Our
focus group questioning route, as shown in Table S3 in
Multimedia Appendix 1, will mirror the key domains in the
national survey and the interviews to allow for the triangulation
of data. The SAB will review the focus group script prior to
IRB submission and implementation.
To obtain perceptions on the ethics of incentives in research,
we will conduct 12 key informant interviews (with up to 36
informants in total or until thematic saturation is achieved) with
each of the following three stakeholder groups: people living
with HIV from across the United States, biomedical HIV
researchers, and IRB members and bioethicists. Each interview
will last approximately 1 hour, will be conducted via
videoconferencing, and will be recorded. Interview participants
will receive a US $25 gift card.
Professional informants (eg, biomedical researchers and IRB
members and bioethicists) will be individually interviewed
one-on-one, as we believe that they will be more likely to share
https://www.researchprotocols.org/2021/11/e33608
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information that they might not openly share with other
participants. Key informant interviews have high data yields,
are easier to coordinate and transcribe, and provide the flexibility
to explore emerging themes while collecting information from
knowledgeable individuals [38,39]. We will develop and adapt
informed consent forms and interview guides for each category
of key informants. The SAB will review the guides prior to IRB
submission and implementation.
The main goal of the data analysis will be to generate a list of
factors that are deemed the most important to consider when
thinking about incentives in HIV research. The qualitative
analysis will rely primarily on grounded theory, which seeks to
understand the realities grounded in the views of study
participants [40]. We will develop a codebook to systematically
analyze the data and identify data-driven (or emergent and
latent) codes [41]. Code development will be an inductive and
iterative process. As relationships among different themes and
subthemes become evident, narratives will be combined into
general concepts to summarize key informants’ perceptions.
We will perform analyses by using MAXDQA software (version
12.1.3; VERBI Software GmbH).

Aim 2: CJA
CJA is a consumer market-based methodology that was designed
to determine the relative “weight” of the characteristics that
influence a consumer’s decision to purchase a product or service.
CJA follows 2 fundamental assumptions. First, when choosing
among very similar products or services, consumers make
choices based on the interconnected (ie, conjoined)
characteristics that make up products and services and make
trade-offs among the characteristics, leading to a product
preference. Second, consumers’ product and service preferences
are created in a rational way, and consumers preferentially select
products and services that increase personal benefits and
minimize personal costs. This is referred to as the theory of
random utility maximization [42]. We consider patient partners
to be “consumers” and research studies to be “products” or
“services.” When deciding whether to participate in a research
study, potential participants make trade-offs among the various
study characteristics in a rational way to increase their personal
benefits and decrease their personal costs.
CJA is methodologically well suited to help us determine which
factors stakeholders consider the most important when choosing
incentives and the relative importance of these factors, as this
type of analysis can be conducted to efficiently measure the
degrees of influence that different factors have on a respondent’s
decision-making [43]. Furthermore, CJA has been used to
effectively predict preferences for and the acceptability of a
wide range of medical services and constructs, including disease
treatments and health care systems [44-53]. It has also been
used to predict real-world outcomes, such as patients’ actual
HIV medication choices [54], and in the assessment of
hypothetical biomedical HIV interventions [55,56].
The ability of CJA to accurately reflect and predict consumer
preferences is heavily dependent on the type of people
participating in the CJA experiment and the selection of study
characteristics. The participants in our CJA experiments will
be people who have participated or would consider participating
JMIR Res Protoc 2021 | vol. 10 | iss. 11 | e33608 | p. 5
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in biomedical research, thereby increasing the generalizability
of the results to a real-world setting. Each attribute will have
different values (referred to as levels in CJA) from which
participants must choose. For example, the risk characteristic
may have 3 levels—no risk, minimal risk, and moderate
risk—whereas the incentive received per clinical study
interaction may have the values none, US $50, or US $100. The
attributes and levels used in our CJA exercises will be
determined via extensive consultation with our SAB, people
living with HIV, IRB members and bioethicists, and researchers
and after a thorough review of relevant research literature.
The selected attributes and levels will be programmed into
Sawtooth Software’s choice-based conjoint program (Lighthouse
Studio 9, version 9.11.0). Participants in the CJA will be asked
to complete an exercise in which they are presented with
multiple hypothetical studies or scenarios and must decide
whether they would consider participating. Each hypothetical
study will be presented as a finite set of attributes that vary in
value, as depicted in Table S4 in Multimedia Appendix 1.
Participants will demonstrate their preferences for these studies
by completing exercises that force trade-offs among similar
studies with the same attributes, but the attributes will differ in
value across the studies. Scenarios will be presented randomly
to prevent order effect bias.
This exercise will allow us to estimate the relative influence
that each attribute has on the decisions of each person
participating in each hypothetical study. For example, the level
of risk associated with participating in a research study may
carry a greater “weight” than that of the frequency of required
study site visits. Data from the CJA exercises will be used to
construct hypothetical scenarios for aim 3.

Aim 3: Develop HIV-Related Vignettes
By using the data collected via aim 2 and the final number of
levels (2-3) per attribute, we will use a factorial design to create
25 hypothetical scenarios (hereafter referred to as vignettes).
For each vignette, the incentive amounts will not be so large or
so small that the answers will be almost unanimous and therefore
predictable. The three research incentive amounts that we
specify will be reasonable choices. A range of US $0 to US
$20,000 is consistent with the studies that we identified in the
literature [57-60].
By using the information collected via aims 1 and 2, the SAB
will help develop the vignettes. We will contrast different types
of HIV studies while being mindful of their parameters, such
as study interventions, perceived risks, participant populations,
and the inconvenience of study visits. We will also integrate 3
comorbidities (depression, heart disease, and arthritis) into the
vignettes to observe differences in decision-making that are
beyond the context of HIV. Four key informant interviewees
from each of the three stakeholder groups (people living with

Galea et al
HIV, IRB members and bioethicists, and researchers: n=12)
will pilot-test the 25 vignettes. Participants will select what they
believe is the most appropriate incentive for each hypothetical
HIV-related vignette (Table S5 in Multimedia Appendix 1).
Research participants will receive US $50 as compensation for
participating in this portion of the study. A linear mixed model
[61] will be used to analyze vignette data, and possible censoring
will be handled by using a maximum likelihood approach.

Demographic Data
Demographic information will be obtained from the national
survey respondents, including age, race and ethnicity, the state
of residence, and the level of educational attainment. Interview,
focus group, and hypothetical study scenario participants will
provide demographic data, which will be linked to their
confidential responses for the purpose of understanding
differences in study data based on key demographic variables.
The demographic survey will be completed after consent is
provided and immediately before beginning the interviews,
focus groups, or hypothetical study scenarios. We will perform
standard descriptive, bivariate, and multivariate analyses on
survey data.

Results
We have convened monthly meetings with the SAB since March
2021, and they helped to cocreate all of the study instruments
and informed consent documents. SAB members are currently
assisting with participant recruitment for focus groups and key
informant interviews. We are also collaborating with the SAB
to develop the attributes and levels that will be programmed
into the CJA software. Data collection and analysis are expected
to be completed by December 2022. The dissemination of our
findings will be accomplished through conferences, community
presentations, the sharing of slide sets, and publications.

Discussion
Given the lack of guidelines that can assist researchers in
ethically incentivizing research participants, it is our hope that
the results of our study will establish a paradigm for all future
clinical research. Integrating HIV comorbidities into our study
will assist in this regard. We will gather pertinent information
by interviewing people living with HIV, IRB members,
bioethicists, and HIV researchers and by conducting a CJA to
determine the relative importance that they place on various
study attributes. We will be able to evaluate what factors
influence an individual’s decision to participate in a research
study by testing decision-making in relation to ethical incentives
via HIV-related vignettes. We hope that our findings will
provide robust empirical data that will guide future ethical
incentive practices in clinical research.
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